UPDATE: Piper Jaffray Raises Price Target on Genomic to $32

According to Piper Jaffray, Genomic Health

price target is raised to $32. Piper Jaffray said that Genomic Health presented positive data on its Oncotype Dx in patients with DCIS (ductal carcinoma in-situ), with data presented at the San Antonio Breast Cancer Symposium meeting its primary endpoint. “We reiterate our Overweight rating on GHDX shares and are increasing our price target to $32 (was $27).” Genomic Health closed yesterday at $29.01.